Sung Soo Mun

Jan 26, 2024 | nature.com | Nathan L. Board |Milica Moskovljevic |Francesco Simonetti |Janet D. Siliciano |Luis Montaner |Sung Soo Mun

AbstractThe persistence of CD4+ T cells carrying latent human immunodeficiency virus-1 (HIV-1) proviruses is the main barrier to a cure. New therapeutics to enhance HIV-1-specific immune responses and clear infected cells will probably be necessary to achieve reduction of the latent reservoir. In the present study, we report two single-chain diabodies (scDbs) that target the HIV-1 envelope protein (Env) and the human type III Fcγ receptor (CD16).